Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings
Shares of Eli Lilly and Company climbed roughly 1.5% on Monday, closing near $1,052.70, after fluctuating between $1,035.28 and $1,056.51 during the session.
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings
Shares of Eli Lilly and Company dropped 1.4% to $1,029.99 by midday Tuesday, sliding from a session peak of $1,048.71 and dipping as low as $1,016.15.
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised
Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom
Healthcare stocks finished last week lower, with XLV — the ETF tracking major U.S. healthcare companies — slipping 0.5% by Friday’s close. Eli Lilly weighed on the sector, though some of the bigger names in the index managed to hold up.
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week
Eli Lilly and Co shares fell on Friday, breaking a brief streak of gains as investors refocused on the ongoing battle in the obesity drug sector that has driven the stock’s recent volatility. The shares closed 2.12% lower at $1,064.29.
Eli Lilly stock slips after hours as obesity-pill race stays in the spotlight
Eli Lilly and Company shares dropped 2.1% on Friday, closing near $1,064.29 in after-hours trading. During the session, the stock swung between $1,094.57 and $1,063.25.
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next
Eli Lilly shares dropped Friday, rattled by investor concerns after rival Novo Nordisk’s Wegovy pill recorded over 18,000 U.S. prescriptions in its first full week on shelves.
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Novo Nordisk A/S shares jumped 4.9% to $62.23 in premarket trading Friday following new data revealing a strong surge in U.S. prescriptions for its Wegovy weight-loss drug. The stock closed Thursday at $59.32.
Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst
Novo Nordisk shares rose 4.3% to 389.95 Danish crowns by 1318 CET on Thursday, recovering most of a steep slide the day before.
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead
Novo Nordisk A/S Class B shares surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news.
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week
Shares of Novo Nordisk jumped 6.49% to 388.90 Danish crowns on Friday, marking their biggest daily gain in weeks. The surge came after new demand signals for its Wegovy obesity drug and a UK approval for a higher Wegovy dose brought the stock back into focus for investors.
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom
U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week
Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33.
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”
Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”
Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus
Novo Nordisk shares climbed 3% to 381.45 Danish crowns on Friday after Amazon Pharmacy announced it will offer the drugmaker’s Wegovy weight-loss pill through insurance coverage as well as a cash-pay option. The U.S.-listed ADRs closed 2.6% higher at $58.81.
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next
Eli Lilly and Company shares dropped 1.99% on Friday, closing at $1,063.56. The stock heads into Monday’s session under pressure after a volatile week for major pharmaceutical firms.
TechStock² Updates
